Literature DB >> 11113943

Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.

P B Gilbert1.   

Abstract

In a preventive vaccine efficacy trial of a vaccine for a genotypically and phenotypically diverse pathogen, it is important to assess if and how vaccine protection against infection or disease varies with characteristics of the exposing pathogen. Gilbert, Self and Ashby developed statistical methods for this problem when the outcome data are counts of the number of vaccinated and unvaccinated trial participants infected by each pathogen strain. However, in many vaccine trials time-to-case information is available, and the extent to which this information improves investigation of differential vaccine protection is unclear. We describe how cause-specific proportional hazards models and other popular competing risks failure time techniques can be applied to this problem. This includes new results on the assumptions required for these methods to give valid inferences about strain-specific vaccine efficacy, and a comparison of theoretical and finite-sample properties between these methods and the time-independent methods. Theoretical considerations, a cholera vaccine trial example, and an extensive simulation study of a human immunodeficiency virus type 1 (HIV-1) vaccine trial show that information about failure times does not appreciably improve estimation or testing unless the pathogen has a high attack rate and the relative prevalence of pathogen strains shifts substantially during the trial follow-up period. An important implication is that practically optimal evaluation of strain-specific vaccine efficacy in HIV-1 vaccine trials will not require knowledge of infection times. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113943     DOI: 10.1002/1097-0258(20001130)19:22<3065::aid-sim600>3.0.co;2-d

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.

Authors:  James Y Dai; Shuying S Li; Peter B Gilbert
Journal:  Biostatistics       Date:  2013-06-27       Impact factor: 5.899

2.  Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

Authors:  D E Neafsey; M Juraska; T Bedford; D Benkeser; C Valim; A Griggs; M Lievens; S Abdulla; S Adjei; T Agbenyega; S T Agnandji; P Aide; S Anderson; D Ansong; J J Aponte; K P Asante; P Bejon; A J Birkett; M Bruls; K M Connolly; U D'Alessandro; C Dobaño; S Gesase; B Greenwood; J Grimsby; H Tinto; M J Hamel; I Hoffman; P Kamthunzi; S Kariuki; P G Kremsner; A Leach; B Lell; N J Lennon; J Lusingu; K Marsh; F Martinson; J T Molel; E L Moss; P Njuguna; C F Ockenhouse; B Ragama Ogutu; W Otieno; L Otieno; K Otieno; S Owusu-Agyei; D J Park; K Pellé; D Robbins; C Russ; E M Ryan; J Sacarlal; B Sogoloff; H Sorgho; M Tanner; T Theander; I Valea; S K Volkman; Q Yu; D Lapierre; B W Birren; P B Gilbert; D F Wirth
Journal:  N Engl J Med       Date:  2015-10-21       Impact factor: 91.245

3.  Estimating and Testing Vaccine Sieve Effects Using Machine Learning.

Authors:  David Benkeser; Peter B Gilbert; Marco Carone
Journal:  J Am Stat Assoc       Date:  2019-04-03       Impact factor: 5.033

4.  Sieve analysis using the number of infecting pathogens.

Authors:  Dean Follmann; Chiung-Yu Huang
Journal:  Biometrics       Date:  2017-12-14       Impact factor: 2.571

5.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.

Authors:  Susan Zolla-Pazner; Paul T Edlefsen; Morgane Rolland; Xiang-Peng Kong; Allan deCamp; Raphael Gottardo; Constance Williams; Sodsai Tovanabutra; Sandra Sharpe-Cohen; James I Mullins; Mark S deSouza; Nicos Karasavvas; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Punnee Pitisuttihum; Jaranit Kaewkungwal; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Jerome H Kim; Peter Gilbert
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

6.  Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated.

Authors:  Dean Follmann; Michael Fay; Craig Magaret
Journal:  Stat Med       Date:  2022-04-08       Impact factor: 2.497

7.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

8.  Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis.

Authors:  Paul T Edlefsen
Journal:  Comput Math Methods Med       Date:  2014-05-07       Impact factor: 2.238

9.  Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Authors:  Paul T Edlefsen; Morgane Rolland; Tomer Hertz; Sodsai Tovanabutra; Andrew J Gartland; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Raphael Gottardo; Michal Juraska; Connor McCoy; Brendan B Larsen; Eric Sanders-Buell; Chris Carrico; Sergey Menis; Gustavo H Kijak; Meera Bose; Miguel A Arroyo; Robert J O'Connell; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Supachai Rerks-Ngarm; Merlin L Robb; Tatsiana Kirys; Ivelin S Georgiev; Peter D Kwong; Konrad Scheffler; Sergei L Kosakovsky Pond; Jonathan M Carlson; Nelson L Michael; William R Schief; James I Mullins; Jerome H Kim; Peter B Gilbert
Journal:  PLoS Comput Biol       Date:  2015-02-03       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.